This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Spellberg, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Spellberg, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMPHOTERICIN B
*LECITHIN

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1573-1576, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01488-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis{triangledown}

Ashraf S. Ibrahim,1,2* Teclegiorgis Gebremariam,1 Mohamed I. Husseiny,1 David A. Stevens,3,4 Yue Fu,1,2 John E. Edwards Jr.,1,2 and Brad Spellberg1,2

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California—Los Angeles Medical Center, Torrance, California,1 David Geffen School of Medicine, University of California—Los Angeles, Los Angeles, California,2 Division of Infectious Diseases, Santa Clara Valley Medical Center, San Jose, California,3 Stanford University School of Medicine, Stanford, California4

Received 15 November 2007/ Returned for modification 13 January 2008/ Accepted 20 January 2008

We compared the efficacies of liposomal amphotericin B (LAmB) and an amphotericin B lipid complex (ABLC) in diabetic ketoacidotic (DKA) or neutropenic mice with disseminated zygomycosis. ABLC was as effective as LAmB in neutropenic but not DKA mice. Low-dose ABLC was less effective than LAmB at reducing brain fungal burdens in both models.

* Corresponding author. Mailing address: Division of Infectious Diseases, Harbor-UCLA Medical Center, 1124 West Carson St., St. John's Cardiovascular Research Center, Torrance, CA 90502. Phone: (310) 222-6424. Fax: (310) 782-2016. E-mail: ibrahim{at}labiomed.org

{triangledown} Published ahead of print on 28 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1573-1576, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01488-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Rodriguez, M. M., Calvo, E., Marine, M., Pastor, F. J., Fernandez-Ballart, J., Guarro, J. (2009). Efficacy of Liposomal Amphotericin B Combined with Gamma Interferon or Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Systemic Zygomycosis in Mice. Antimicrob. Agents Chemother. 53: 3569-3571 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»